Cumberland Pharma

Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company, which engages in the acquisition, development, and commercialization of prescription products. Its product include Acetadote, Caldolor, Kristalose, Omeclamox, Vaprisol, Vibativ, and RediTrex. The company was founded by A. J. Kazimi on January 6, 1999 and is headquartered in Nashville, TN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cumberland Pharma reports steady Q1 performance amidst sales challenges

Cumberland Pharma's Q1 2024 performance showcased resilience in the face of sales challenges, with a strategic emphasis on FDA-approved brands. The company's dedication to innovation and patient care underpins its growth trajectory, despite hurdles posed by insurance deductibles.

Cumberland Pharma reports revenue growth but faces profitability challenges

Cumberland Pharmaceuticals demonstrated revenue growth potential but grappled with profitability challenges in Q2 2024. The company's focus on innovation, market expansion, and patient care underscores a commitment to long-term success. Addressing cost management, profitability, and leveraging growth opportunities will be crucial for Cumberland's future.

Cumberland Pharma reports resilient Q3 performance amidst operational challenges

Cumberland Pharma's Q3 2024 performance was driven by FDA-approved brands despite challenges.
The company showcased improved financials with a focus on operational efficiency and growth opportunities.
While facing challenges like product returns and expenses, Cumberland maintains a strong financial position.
Strategic initiatives and research efforts position Cumberland for future growth and profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company, which focuses on the acquisition, development, and commercialization of branded prescription pharmaceutical products. Its products include Acetadote, Caldolor, Kristalose, Omeclamox, Vaprisol, Vibativ, Sancuso, Boxaban, Vasculan. Dyscorban, and RediTrex. The company was founded by A. J. Kazimi on January 7, 1999 and is headquartered in Nashville, TN.

NASHVILLE, Tenn., June 21, 2021 /PRNewswire/ --Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today released a series of case reports describing the effectiveness of Vibativ® (telavancin) in treating secondary bacterial infections in COVID-19 patients – particularly those with other significant health problems, such as obesity, diabetes and heart disease.

Vibativ® Effectively Helps Treat Secondary Bacterial Infections In COVID-19 Patients

Cumberland (CPIX) could produce exceptional returns because of its solid growth attributes.

Is Cumberland (CPIX) a Solid Growth Stock? 3 Reasons to Think " Yes "

NASHVILLE, Tenn., May 19, 2021 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that it has promoted John Hamm to  Director Finance & Accounting and Chief Financial Officer.

Cumberland Pharmaceuticals Names John Hamm New Chief Financial Officer

Cumberland Pharmaceuticals, Inc. (CPIX) CEO A. J. Kazimi on Q1 2021 Results - Earnings Call Transcript

Shares of Cumberland (NASDAQ:CPIX) moved higher in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 600.00% over the past year to $0.07, which beat the estimate of ($0.07).

Cumberland: Q1 Earnings Insights

NASHVILLE, Tenn., May 11, 2021 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today is providing a company update and first quarter 2021 financial results.

Cumberland Pharmaceuticals Reports First Quarter 2021 Financial Results & Company Update

Cumberland (NASDAQ:CPIX) announces its next round of earnings this Tuesday, May 11. Here is Benzinga's look at Cumberland's Q1 earnings report.

Preview: Cumberland's Earnings

NASHVILLE, Tenn., May 4, 2021 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release first quarter 2021 financial results and Company update after the market closes on Tuesday, May 11, 2021.

Cumberland Pharmaceuticals To Announce First Quarter 2021 Financial Results

Seattle-based Tegria, a healthcare services and tech company that Providence launched last year, announced the acquisition of Franklin, Tenn.

Providence's Tegria adds another company, acquires healthcare consulting firm Cumberland

Cumberland Pharmaceuticals, Inc. (CPIX) CEO A. J. Kazimi on Q4 2020 Results - Earnings Call Transcript

Cumberland (CPIX) delivered earnings and revenue surprises of 200.00% and 4.93%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Cumberland Pharmaceuticals (CPIX) Beats Q4 Earnings and Revenue Estimates

Shares of Cumberland (NASDAQ:CPIX) moved higher in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 88.89% over the past year to $0.01, which beat the estimate of ($0.01).

Recap: Cumberland Q4 Earnings

NASHVILLE, Tenn., March 9, 2021 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care, gastroenterology and rheumatology, today announced fourth quarter and full year 2020 financial results.

Cumberland Pharmaceuticals Reports 9% Revenue Growth In 2020

Cumberland (NASDAQ:CPIX) announces its next round of earnings this Tuesday, March 09. Here is Benzinga's look at Cumberland's Q4 earnings report.

Cumberland Earnings Preview

NASHVILLE, Tenn., March 2, 2021 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release fourth quarter and annual 2020 financial results and Company update after the market closes on Tuesday, Mar. 9, 2021. A conference call and live internet...

Cumberland Pharmaceuticals To Announce Fourth Quarter And Annual 2020 Financial Results

The 800+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the third quarter, which unveil their equity positions as of September 30. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund portfolios. Our extensive review of these public filings is finally over, so this article is set to reveal the smart money sentiment towards Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX).

Where Do Hedge Funds Stand On Cumberland Pharmaceuticals, Inc. (CPIX)?

NASHVILLE, Tenn., Nov. 17, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a U.S. specialty pharmaceutical company, announced today the launch of RediTrex® (methotrexate) injection. RediTrex is a new line of pre-filled syringes specifically designed for ease of...

Introducing RediTrex®, A New Methotrexate Delivery System

Cumberland Pharmaceuticals, Inc. (CPIX) CEO A. J. Kazimi on Q3 2020 Results - Earnings Call Transcript

Cumberland (CPIX) delivered earnings and revenue surprises of 128.57% and 7.45%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Cumberland Pharmaceuticals (CPIX) Q3 Earnings and Revenues Surpass Estimates

Shares of Cumberland (NASDAQ:CPIX) were flat after the company reported Q3 results. Quarterly Results Earnings per share increased 100.00% over the past year to $0.02, which beat the estimate of ($0.07).

Recap: Cumberland Q3 Earnings

NASHVILLE, Tenn., Nov. 10, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today is providing a company update and third quarter 2020 financial results. Net revenues from continuing operations during the quarter were $9.3 million....

Cumberland Pharmaceuticals Reports Third Quarter 2020 Financial Results & Company Update

Cumberland (NASDAQ: CPIX) unveils its next round of earnings this Tuesday, November 10. Get prepared with Benzinga's ultimate preview for Cumberland's Q3 earnings.

Cumberland's Earnings: A Preview

NASHVILLE, Tenn., Nov. 3, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release third quarter 2020 financial results and Company update after the market closes on Tuesday, Nov. 10, 2020. A conference call and live internet webcast will be...

Cumberland Pharmaceuticals To Announce Third Quarter 2020 Financial Results

Cumberland (CPIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Cumberland Pharmaceuticals (CPIX) Q3 Earnings Expected to Decline

ATLANTA, Sept. 28, 2020 /PRNewswire/ -- Women's apparel and fashion accessories retailer, Charming Charlie, today announced that it will open its first physical store at the Cumberland Mall in Atlanta, Georgia. Charming Charlie will welcome back existing customers and introduce new...

News for Cumberland Pharma Stock (CPIX)